
The STEP1 study included 1961 adults with a body mass index (BMI) of 27 or higher with at least 1 weight-related health condition, or a BMI of 30 or higher, without diabetes.

The STEP1 study included 1961 adults with a body mass index (BMI) of 27 or higher with at least 1 weight-related health condition, or a BMI of 30 or higher, without diabetes.

Researchers found no evidence that protection against COVID-19 reinfection declined within a 6-month follow-up period.

Although childbirth remains a difficult, often stressful experience for mothers, the advent of opioid medications for labor pain relief and the use of appropriate sanitation methods has made childbirth far safer for mothers than was possible during previous periods in history.

In addition to cardiotoxicity from cancer-related treatments, the researchers noted that obesity, cancer, and cardiovascular disease share some common risk factors.

As the pandemic has continued, it has helped shine a light on how important pharmacists, pharmacy interns, and pharmacy technicians can help impact their communities.

Advice for clinical pharmacists who help manage patients with relapsed/refractory multiple myeloma in the current era of novel therapies and recommendations to improve upon current practice patterns.

Novel treatment strategies being explored in clinical trials that look exciting in relapsed/refractory multiple myeloma, and implications for using these newer approaches in the future.

The importance of coordinated care and proper education to pharmacists on best practices when dispensing anti-BMCA therapy to patients with relapsed/refractory multiple myeloma.

Pharmacy Times spoke with Josh Benner, pharmacist and CEO/founder of RxAnte, about medication misuse and the future of pharmacy in 2021.

Digital health products and solutions expand ways to guide prevention and treatment.

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, which activates the innate immune system in the tumor microenvironment and anti-tumor activity.

Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, discusses how pharmacists and other medical professionals can boost their brain health and keep a positive mindset while working during the pandemic.

Although ART has helped improve the health of those with HIV, they are at a greater risk of developing complications related to chronic inflammation, such as cardiovascular disease.

The plot clinical trial included 40 men and is believed to be the first published study to use progesterone to treat male COVID-19 patients whose lung functions have been compromised by the virus.

Shoulder injuries are a real concern because some health care workers may be new to administering vaccines.

Farah Towfic, PharmD, MBA, director, CEO operations at US Pharmacopeia (USP), discusses USP’s release of an updated version of its COVID-19 Vaccine Handling Toolkit in response to feedback from independent pharmacies to mass vaccination clinics.

Fractures, especially subsequent ones, positively correlate with an increased mortality risk.

The COVID-19 pandemic significantly impacted pharmacy practice due to its role in supporting overwhelmed physicians, nurses, and other health care professionals who faced some of the immediate challenges of the crisis.

A new study published in The American Journal of Clinical Nutrition found that for colorectal cancer survivors, maintaining a stable body weight may hide a loss of muscle and the development of fatty deposits in their muscles, which resulted in a 40% higher risk of premature death.

Pharmacies can reach patients who are not receiving vaccines from a pharmacy but are willing to receive them.

With the breakthrough device designation granted in 2019, the Signatera MRD test now has 3 designations for use across several cancer types and indications.

Technology is essential, but not all solutions meet every goal or offer the same capabilities.

If IVIG is commenced within 2 weeks from the onset of Guillain-Barre syndrome it can hasten recovery as much as plasma exchange, study indicates.

Results from the phase 3 KEYNOTE-775/study 309 trial found that Keytruda plus Lenvima reduced risk of death by 38%, with a median overall survival of 18.3 months

The FDA has approved the submission of a supplemental new drug application (sNDA) that expands the use of bupivacaine liposome injectable suspension to include patients aged 6 years and older for single-dose infiltration as a postsurgical local analgesia.

More than ever, confidence in objective, science-based data about therapeutics, such as the COVID-19 vaccine and other health care services, is a shared imperative across the pharmaceutical industry, health care communities, and the American public.

This vaccine rollout has become even more crucial for the US health care system, as new mutations of the coronavirus continue to emerge.

New results show that non-Hispanic Black patients with COVID-19 and type 1 diabetes have an additional risk of diabetic ketoacidosis beyond the risk of having diabetes or being of minority status.

Results from a phase 3 trial investigating the programmed cell death protein 1 inhibitor cemiplimab monotherapy compared to chemotherapy showed an overall survival benefit among patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.

Electricity may slow the speed at which breast cancer cells spread through the body, and in some cases may stop them entirely, according to a new study published in Bioelectricity.